Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0031 | 0.5102 | 0.5 | |
Echinococcus granulosus | lamin | 0.0031 | 0.5102 | 0.5102 |
Echinococcus granulosus | intermediate filament protein | 0.0031 | 0.5102 | 0.5102 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.4922 | 0.4922 |
Echinococcus granulosus | lamin dm0 | 0.0031 | 0.5102 | 0.5102 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0031 | 0.5102 | 0.4832 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 1 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0046 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0031 | 0.5102 | 0.5102 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0031 | 0.5102 | 0.5102 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 1 | 1 |
Brugia malayi | intermediate filament protein | 0.0031 | 0.5102 | 0.4832 |
Onchocerca volvulus | 0.0031 | 0.5102 | 0.5 | |
Echinococcus multilocularis | musashi | 0.0031 | 0.5102 | 0.5102 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0031 | 0.5102 | 0.5102 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0016 | 0.0524 | 0.0524 |
Echinococcus multilocularis | lamin | 0.0031 | 0.5102 | 0.5102 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 1 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0031 | 0.5102 | 0.5102 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -5.31 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.135 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -5.131 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.857 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.84 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.746 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.745 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.735 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.